Sha Ha

Dr. Ha is a Director of Vaccine Bioprocess Research & Development at Merck & Co. She manages a portfolio of projects advancing vaccine candidates from research to Phase II clinical development. She is intimately involved in setting analytical strategies for biologics filing, and has extensive experience in charactering and releasing biological products for clinical trials. Before joining Merck, Dr. Ha was a group leader at Bayer Healthcare Pharmaceuticals where she led monoclonal antibody discovery for cancer therapeutics. Dr. Ha received her Ph.D. in Chemistry from Princeton University and her B.S. from Peking University.